Asset Details
Do you wish to reserve the book?
Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
Do you wish to request the book?
Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment
2010
Overview
Pathologically altered stromas are a common contributing factor to cancer progression and fibrogenesis. This report uncovers the role of LOXL2 in the creation and maintenance of the pathological microenvironment of human cancers and fibrotic diseases and presents the development of a LOXL2-specific antibody that shows therapeutic activity in tumor as well as lung and liver fibrosis models.
We have identified a new role for the matrix enzyme lysyl oxidase–like-2 (LOXL2) in the creation and maintenance of the pathologic microenvironment of cancer and fibrotic disease. Our analysis of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-associated stroma and limited expression in healthy tissues. Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models. Inhibition of LOXL2 resulted in a marked reduction in activated fibroblasts, desmoplasia and endothelial cells, decreased production of growth factors and cytokines and decreased transforming growth factor-β (TGF-β) pathway signaling. AB0023 outperformed the small-molecule lysyl oxidase inhibitor β-aminoproprionitrile. The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncologic and fibrotic diseases.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Amino Acid Oxidoreductases - antagonists & inhibitors
/ Amino Acid Oxidoreductases - drug effects
/ Amino Acid Oxidoreductases - genetics
/ Amino Acid Oxidoreductases - metabolism
/ Aminopropionitrile - pharmacology
/ Animals
/ Antibodies, Monoclonal - pharmacology
/ Biomedical and Life Sciences
/ Biopsy
/ Breast Neoplasms - pathology
/ Cancer
/ Enzymes
/ Female
/ Humans
/ Liver
/ Lysine
/ Mice
/ Neoplasm Metastasis - pathology
/ Neoplasm Metastasis - prevention & control
/ Oxidases
